News
Gilead has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two mid-stage trials of ...
Zacks Investment Research on MSN1d
KYMR Collaborates With GILD; Stock Down on Sanofi Deal UpdateKymera Therapeutics, Inc. KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader ...
Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.
A Fierce Pharma Marketing review of the LinkedIn and Instagram pages of the 20 largest pharmas found that, as of Thursday, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback